Vaxxon SRP® SE licensed in USA
Nijmegen, The Netherlands, Wednesday January 22, 2020.
Vaxxinova is pleased to announce that last week the USDA granted Epitopix the license for Vaxxon SRP® SE, a poultry vaccine which has been shown to have an effect against colonization of Salmonella Enteritidis in the reproductive tract. Vaxxon SRP® SE uses innovative siderophore receptor and porin (SRP) technology, developed and patented by Epitopix. It is a purified bacterial extract vaccine comprised of highly conserved SRP proteins as principal antigens, in a low volume vaccine dose.
From January 28-30, 2020 Vaxxinova will be present at IPPE 2020, Booth C10361. Our team welcomes you to come by and find out more on Vaxxon SRP® SE.
More information on Epitopix and SRP® technology is available at http://epitopix.com/
Epitopix is a privately held company based in Willmar, Minnesota, USA, and is an affiliate of Vaxxinova.
Disclaimer: Vaxxon SRP® SE is only available in certain countries. Please contact your local Vaxxinova representative for more information.